Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;24(4):317-23.
doi: 10.1016/S1674-8301(10)60044-9.

The effects of diltiazem in renal transplantation patients treated with cyclosporine A

Wujun Xue  1 , Yong Song, Puxun Tian, Xiaoming Ding, Xiaoming Pan, Hang Yan, Jun Hou, Xinshun Feng, Heli Xiang, Xiaohui Tian
Affiliations

The effects of diltiazem in renal transplantation patients treated with cyclosporine A

Wujun Xue et al. J Biomed Res. 2010 Jul.

Abstract

Objective: To investigate the effects of diltiazem and cyclosporine A (CsA) combination therapy on protecting the kidney, promoting graft functioning and improving post-transplanted kidney recovery.

Methods: The blood concentrations of CsA, the condition of the post-transplant kidney, the rate of acute rejection (AR), as well as hepatic and renal toxicity in 636 cases of renal transplant recipients were determined after being treated by CsA, with or without diltiazem.

Results: Compared with the control group which received CsA, mycophenolate mofetil (MMF) and prednisolone (Pred) but lacked diltiazem, the group receiving these agents together with diltiazem required reduced dosage of CsA (P < 0.01), while blood concentrations of CsA were significantly increased (P < 0.01); the recovery time of graft function was reduced from (6.2±1.5) d to (3.9±1.4) d (P < 0.01), and the rate of AR was decreased from 13.2% to 7.9% (P < 0.01).

Conclusion: In renal transplantation patients treated with CsA and diltiazem, blood concentrations of CsA were increased while the dosage was decreased. This efficient combination therapy reduced patients' economic burden, at the same time retained kidney function, promoted graft function recovery and decreased hepatic and renal toxicity and the rate of AR.

Keywords: cyclosporine A; diltiazem; transplant/kidney.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Comparison of the ratio of AR between the treatment group and control group.
The rate of AR in the treatment group was significantly lower than that in the control group, especially at month 3 and 6.
See this image and copyright information in PMC

References

    1. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538–49. - PubMed
    1. Fernandes I, Zhang Y, Qi Y, Wang ME, Podder H, Lisik W, et al. Impact of reduced nephron mass on cyclosporine- and/or sirolimus-induced nephrotoxicity. Transplantation. 2009;88:1323–31. - PubMed
    1. Gupta SK, Benet LZ. High-fat meals increase the clearance of cyclosporine. Pharm Res. 1990;7:46–8. - PubMed
    1. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24:330–50. - PubMed
    1. Foradori A, Mezzano S, Videla C, Pefaur J, Elberg A. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Transplant Proc. 1998;30:1685–7. - PubMed